Navigation Links
K-V Pharmaceutical Company Announces Completion of a $32 Million Private Placement of Class A Common Stock
Date:2/14/2011

ST. LOUIS, Mo., Feb. 14, 2011 /PRNewswire/ -- K-V Pharmaceutical Company (NYSE:  KVa/KVb) (the "Company") today announced that it has entered into a definitive agreement with a group of institutional investors to raise approximately $32 million of gross proceeds from a private placement of 9,950,000 shares of its Class A Common Stock at $3.25 per share. The Company will use $20 million of the proceeds from the financing to repay certain outstanding amounts and other outstanding obligations under its credit agreement with U.S. Healthcare and the remainder for general corporate purposes, including the launch of Makena™. Subject to the satisfaction of customary closing conditions, the private placement is expected to close and fund on or about February 17, 2011.  

The Company also announced it has agreed to terms with US Healthcare I, L.L.C. and US Healthcare II, L.L.C., affiliates of New York based Centerbridge Partners, L.P. to close on a multi-draw financing facility with a total commitment of $130 million. The amendment is expected to be completed on or prior to February 18, 2011.  In addition, the Company has agreed to issue additional warrants to purchase 7,450,899 shares of the Company's Class A Common Stock, subject to completion of the private placement, at an exercise price of $1.62 per share.

Upon completion of the definitive agreement, the loan terms and covenants will be amended to reflect the Company's current projections and timing of certain anticipated future events, including the planned disposition of certain assets.  The significant components of the amended agreement will include extending the $60 million payment that was due on March 20, 2011 to three payments of $20 million each with the first payment due upon closing and funding the private placement, $20 million due in April 2011 and $20 million due in August 2011.  In addition, all past covenant issues will be waived.  In addition to the loa
'/>"/>

SOURCE K-V Pharmaceutical Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  XBiotech announced ... study being conducted in the US for its ... Human™ monoclonal antibody therapy, is being evaluated in ... complicated with cachexia. The primary endpoint of the ... treated patients to a control population provided only ...
(Date:9/2/2014)...   Santa Clara dentist , Dr. Alan ... Invisalign. Invisalign is an orthodontic system that uses clear ... the orthodontic treatment of choice for older teens and ... For a limited time, patients can try Invisalign for ... usual cost. This offer cannot be combined, and some ...
(Date:9/2/2014)... , September 2, 2014 ... CONGRESS 2014 provide insight into treatment and outcomes ... clinical practice --   Data from ... Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF), an innovative, ... prevention strategies for atrial fibrillation (AF) patients remain ...
Breaking Medicine Technology:XBiotech Halts Study, Reports Positive Phase III Results with Antibody Therapy for Cancer 2Santa Clara Cosmetic Dentist, Dr. Alan Frame, is Now Offering a Special on Invisalign 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9
... CANTEL MEDICAL CORP. (NYSE: CMN ) ... per diluted share, on a 24% increase in sales to a ... compares with net income of $4,274,000, or $0.25 per diluted share, ... 2010.  For the nine months ended April 30, 2011, the Company ...
... Pa., June 8, 2011 TetraLogic Pharmaceuticals, a biopharmaceutical ... treat cancer, today announced the appointment of Mr. Jonathan ... and vice president of corporate development. ... of corporate development and finance experience.  He has led ...
Cached Medicine Technology:Cantel Medical Reports 18% Increase in Net Income on 24% Increase in Sales 2Cantel Medical Reports 18% Increase in Net Income on 24% Increase in Sales 3Cantel Medical Reports 18% Increase in Net Income on 24% Increase in Sales 4Cantel Medical Reports 18% Increase in Net Income on 24% Increase in Sales 5TetraLogic Appoints Jonathan B. Lloyd Jones as Chief Financial Officer and Vice President Corporate Development 2
(Date:9/2/2014)... in California, the percentage undergoing a double mastectomy increased ... not associated with a lower risk of death than ... the September 3 issue of JAMA . The ... one breast was associated with a higher risk of ... , Randomized trials have demonstrated similar survival for patients ...
(Date:9/2/2014)... cancer cells can lay the groundwork for their own ... vessels to send out tumor-welcoming signals, according to a ... the Sept. 2 issue of Nature Communications , ... increased levels of so-called signaling molecules released by breast ... in the lungs and lymph nodes to produce proteins ...
(Date:9/2/2014)... Medex Analytic Services is delighted to ... Coral Springs, Fla. due to their greater than forecasted ... for the 2014 year by distinguishing Medex in the ... a higher level of service and professionalism in the ... the industry has responded.” , The location of the ...
(Date:9/2/2014)... (PRWEB) September 03, 2014 Operators in ... to millions of people annually, arranging care and counsel ... and private enterprises are expected to derive $39.4 billion ... donations and private income. Over the five years through ... annualised rate of 6.6%, including growth of 4.1% in ...
(Date:9/2/2014)... new studies further confirm the health benefits of breast-feeding. ... a lower risk of ear, throat and sinus infections ... similar trend when it comes to allergies. The ... immediate newborn period," said Dr. Jennifer Wu, an obstetrician-gynecologist ... was not involved in the new studies. The ...
Breaking Medicine News(10 mins):Health News:Increase seen in use of double mastectomy 2Health News:Increase seen in use of double mastectomy 3Health News:‘Prepped’ by tumor cells, lymphatic cells encourage breast cancer cells to spread 2Health News:Medex Analytic Services Announces New Location for Corporate Headquarters 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:More Evidence Breast-Feeding Lowers Child's Risk of Infections, Allergies 2
... of "color-coded" laboratory mice are providing researchers with a ... and monitor the cellular immune responses of transplanted tissue ... in the June issue of Nature Medicine , ... are a key consideration in developing strategies to improve ...
... release is available in Spanish . , ... , from the Department of Physiology of the University ... Castillo Garzn . To carry out this project, the researcher ... and Assessment of Nutritional Status of Spanish Adolescents) and HELENA ...
... ... Cancer joins Cyberknife of Long Island , ... (PRWEB) May 27, 2010 -- Cyberknife of Long Island treats tumors ... Accuray offers unprecedented capabilities and renewed hope to prostate cancer patients. Cyberknife ...
... sex, still urged, experts say, , THURSDAY, May 27 (HealthDay ... for transmitting the virus to their partners by 90 percent ... Antiretroviral drug therapy helps reduce HIV levels in the infected ... to others. The drugs are commonly taken in the United ...
... in end-stage cardiac patients has a significantly lower risk for ... researchers at Henry Ford Hospital in Detroit. Known as ... HeartMate ,is much smaller than the first and uses a ... itself, to continually push blood through the body. Its predecessor ...
... ... no longer have access to per incident technical support services , ... (PRWEB) May 27, 2010 -- In a recent announcement ... Avaya maintenance agreement will no longer have access to per incident technical support services which ...
Cached Medicine News:Health News:Color-coded tracking method helps scientists analyze outcomes of newly transplanted tissue 2Health News:Color-coded tracking method helps scientists analyze outcomes of newly transplanted tissue 3Health News:Researchers validate a new test for assessing children's and teenagers' fitness to prevent morbidity 2Health News:Cyberknife of Long Island Destroys Prostate Cancer Non-Invasively Using Radiosurgery 2Health News:Cyberknife of Long Island Destroys Prostate Cancer Non-Invasively Using Radiosurgery 3Health News:Anti-HIV Drugs May Help Prevent Spread of Virus 2Health News:Henry Ford Hospital study: Fewer infections with new heart-pump implant 2Health News:Avaya Announces End of Support to Non Maintenance Customers 2
Livewire TC steerable ablation catheters are designed for the RF ablation of arrhythmias. They are available in a variety of curves and configurations, including bi-directional catheters for added fl...
Trilogy Pacemakers incorporates the clinically proven Omniscence™ accelerometer sensor with it's automatic alogorithms. The Trilogy family of pacemakers feature an array of products for bradyar...
... The Integrity ADx ... the world's smallest dual-chamber ... advanced pacemaker technology, including ... algorithm, the first U.S. ...
... Frontier II device is designed ... moderate to severe heart failure ... in patients who are symptomatic ... and who have prolonged QRS ...
Medicine Products: